Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy

BACKGROUND AND OBJECTIVE: Discontinuation of fingolimod ≥2 months before pregnancy is recommended to minimize potential teratogenicity. The magnitude of MS pregnancy relapse risk, particularly severe relapses, after fingolimod cessation is unclear, as is whether this risk is reduced by pregnancy or...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellwig, Kerstin, Tokic, Marianne, Thiel, Sandra, Hemat, Spalmai, Timmesfeld, Nina, Ciplea, Andrea I., Gold, Ralf, Langer-Gould, Annette M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202774/
https://www.ncbi.nlm.nih.gov/pubmed/37217309
http://dx.doi.org/10.1212/NXI.0000000000200110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202774/
https://www.ncbi.nlm.nih.gov/pubmed/37217309
http://dx.doi.org/10.1212/NXI.0000000000200110

Ejemplares similares